196 related articles for article (PubMed ID: 19383925)
21. Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit.
Verstovsek S; Akin C; Manshouri T; Quintás-Cardama A; Huynh L; Manley P; Tefferi A; Cortes J; Giles FJ; Kantarjian H
Leuk Res; 2006 Nov; 30(11):1365-70. PubMed ID: 16797704
[TBL] [Abstract][Full Text] [Related]
22. Stem cell factor as a survival and growth factor in human normal and malignant hematopoiesis.
Hassan HT; Zander A
Acta Haematol; 1996; 95(3-4):257-62. PubMed ID: 8677752
[TBL] [Abstract][Full Text] [Related]
23. [Treatment with a tyrosine-kinase inhibitor of for c-KIT mutation and AML1-ETO double positive refractory acute myeloid leukemia].
Ueyama J; Kure A; Okuno K; Sano H; Tamoto N; Kanzaki S
Rinsho Ketsueki; 2012 Apr; 53(4):460-4. PubMed ID: 22687981
[TBL] [Abstract][Full Text] [Related]
24. Genetic and pharmacologic evidence implicating the p85 alpha, but not p85 beta, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis.
Munugalavadla V; Sims EC; Borneo J; Chan RJ; Kapur R
Blood; 2007 Sep; 110(5):1612-20. PubMed ID: 17483298
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia.
Kindler T; Breitenbuecher F; Marx A; Beck J; Hess G; Weinkauf B; Duyster J; Peschel C; Kirkpatrick CJ; Theobald M; Gschaidmeier H; Huber C; Fischer T
Blood; 2004 May; 103(10):3644-54. PubMed ID: 14726395
[TBL] [Abstract][Full Text] [Related]
26. The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling.
Warshamana-Greene GS; Litz J; Buchdunger E; Hofmann F; García-Echeverría C; Krystal GW
Mol Cancer Ther; 2004 May; 3(5):527-35. PubMed ID: 15141010
[TBL] [Abstract][Full Text] [Related]
27. SAR103168: a tyrosine kinase inhibitor with therapeutic potential in myeloid leukemias.
Bourrié B; Brassard DL; Cosnier-Pucheu S; Zilberstein A; Yu K; Levit M; Morrison JG; Perreaut P; Jegham S; Hilairet S; Bouaboula M; Penarier G; Guiot C; Larroze-Chicot P; Laurent G; Demur C; Casellas P
Leuk Lymphoma; 2013 Jul; 54(7):1488-99. PubMed ID: 23121564
[TBL] [Abstract][Full Text] [Related]
28. c-Kit is preferentially expressed in MYCN-amplified neuroblastoma and its effect on cell proliferation is inhibited in vitro by STI-571.
Vitali R; Cesi V; Nicotra MR; McDowell HP; Donfrancesco A; Mannarino O; Natali PG; Raschellà G; Dominici C
Int J Cancer; 2003 Aug; 106(2):147-52. PubMed ID: 12800187
[TBL] [Abstract][Full Text] [Related]
29. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.
Woodman SE; Trent JC; Stemke-Hale K; Lazar AJ; Pricl S; Pavan GM; Fermeglia M; Gopal YN; Yang D; Podoloff DA; Ivan D; Kim KB; Papadopoulos N; Hwu P; Mills GB; Davies MA
Mol Cancer Ther; 2009 Aug; 8(8):2079-85. PubMed ID: 19671763
[TBL] [Abstract][Full Text] [Related]
30. Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylate.
Kosmider O; Denis N; Dubreuil P; Moreau-Gachelin F
Oncogene; 2007 May; 26(26):3904-8. PubMed ID: 17173066
[TBL] [Abstract][Full Text] [Related]
31. Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis.
González I; Andreu EJ; Panizo A; Inogés S; Fontalba A; Fernández-Luna JL; Gaboli M; Sierrasesúmaga L; Martín-Algarra S; Pardo J; Prósper F; de Alava E
Clin Cancer Res; 2004 Jan; 10(2):751-61. PubMed ID: 14760098
[TBL] [Abstract][Full Text] [Related]
32. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells.
Nam S; Williams A; Vultur A; List A; Bhalla K; Smith D; Lee FY; Jove R
Mol Cancer Ther; 2007 Apr; 6(4):1400-5. PubMed ID: 17431118
[TBL] [Abstract][Full Text] [Related]
33. Tyrosine kinase inhibitors induce down-regulation of c-Kit by targeting the ATP pocket.
D'allard D; Gay J; Descarpentries C; Frisan E; Adam K; Verdier F; Floquet C; Dubreuil P; Lacombe C; Fontenay M; Mayeux P; Kosmider O
PLoS One; 2013; 8(4):e60961. PubMed ID: 23637779
[TBL] [Abstract][Full Text] [Related]
34. Identification of novel target genes of nerve growth factor (NGF) in human mastocytoma cell line (HMC-1 (V560G c-Kit)) by transcriptome analysis.
Dutta P; Koch A; Breyer B; Schneider H; Dittrich-Breiholz O; Kracht M; Tamura T
BMC Genomics; 2011 Apr; 12():196. PubMed ID: 21501463
[TBL] [Abstract][Full Text] [Related]
35. Novel thiazole amine class tyrosine kinase inhibitors induce apoptosis in human mast cells expressing D816V KIT mutation.
Jin Y; Ding K; Wang D; Shen M; Pan J
Cancer Lett; 2014 Oct; 353(1):115-23. PubMed ID: 25088577
[TBL] [Abstract][Full Text] [Related]
36. KIT receptor activation by autocrine and paracrine stem cell factor stimulates growth of merkel cell carcinoma in vitro.
Krasagakis K; Fragiadaki I; Metaxari M; Krüger-Krasagakis S; Tzanakakis GN; Stathopoulos EN; Eberle J; Tavernarakis N; Tosca AD
J Cell Physiol; 2011 Apr; 226(4):1099-109. PubMed ID: 20857409
[TBL] [Abstract][Full Text] [Related]
37. Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970.
Corbin AS; Griswold IJ; La Rosée P; Yee KW; Heinrich MC; Reimer CL; Druker BJ; Deininger MW
Blood; 2004 Dec; 104(12):3754-7. PubMed ID: 15304388
[TBL] [Abstract][Full Text] [Related]
38. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia.
Goemans BF; Zwaan CM; Miller M; Zimmermann M; Harlow A; Meshinchi S; Loonen AH; Hählen K; Reinhardt D; Creutzig U; Kaspers GJ; Heinrich MC
Leukemia; 2005 Sep; 19(9):1536-42. PubMed ID: 16015387
[TBL] [Abstract][Full Text] [Related]
39. Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia.
Faderl S; Harris D; Van Q; Kantarjian HM; Talpaz M; Estrov Z
Blood; 2003 Jul; 102(2):630-7. PubMed ID: 12663443
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M
Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
